Capricor Therapeutics Inc(CAPR)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$28.22
- 52-Week Range
- $4.30 – $40.37
- YTD
- -0.31%
- IV Rank (30D)
- 20.23
- Straddle Price
- $7.03
- P/C Vol Ratio
- 0.51
- Market Cap
- $1.5B
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.48% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.98% (VRP-adj) |
| WACC | 10.00% |
| Volatility Risk Premium | +49.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -41.1% |
| Book / Price | 21.9% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $30.73 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $27.56 |
| Bollinger Width / SMA20 | 79.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $1B |
Peers used for multiples: ALKS, ARWR, EXEL, KRYS, RVMD, TGTX, TVTX, TWST
Blended Fair Value
$69.20
Current Price
$28.16
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 29.6× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 49.2× · 5 peers |
| Peer P/B | $69.20 | 100% | median 12.1× · 8 peers |
| Peer P/S | n/a | 0% | median 11.0× · 7 peers |
| Market Anchor (SMA50) | $30.73 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-17 · updated 2026-06-17 18:33:31.317000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $1.5B
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM …
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +11.67% | 11 |
| Feb | +0.54% | 11 |
| Mar | -0.78% | 12 |
| Apr | +42.58% | 12 |
| May | -14.12% | 12 |
| Jun | +2.74% | 12 |
| Jul | +7.10% | 11 |
| Aug | +1.52% | 11 |
| Sep | +33.36% | 11 |
| Oct | -11.62% | 11 |
| Nov | -10.68% | 11 |
| Dec | +27.57% | 11 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $27.62
SMA 50: $30.65
SMA 200: $21.27
Current: $28.07
EMA 12: $26.92
EMA 26: $28.04
MACD: -1.1274 | Signal: 0.1350
BEARISH
ADX (14): 24.13
WEAK TREND
+DI: 22.57
−DI: 24.44
Momentum Oscillators
RSI (14): 49.81
NEUTRAL
Stoch %K: 39.13
Stoch %D: 28.62
Williams %R: -41.74
Volume & Volatility
BB Upper: $30.64
BB Lower: $24.60
NEUTRAL
OBV: 111,150,861
Vol SMA 20: 810,936
Vol ROC: 43.92%
ATR: $1.58
True Range: $2.68
HV 20: 56.2%
HV 30: 62.6%
HV 60: 64.5%
Data Summary
Data Points: 500
Last Updated: 2026-06-17T18:30:15.875000
Date Range: 2024-06-18T00:00:00 – 2026-06-16T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
6 of 7 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-07 | Pre-Market | 150.66% | 7.33% | 0.05x | Within |
| 2024-10-16 | After-Close | 17.20% | 1.39% | 0.08x | Within |
| 2025-03-19 | After-Close | 9.33% | 13.89% | 1.49x | Exceeded |
| 2025-05-13 | After-Close | 15.15% | 5.37% | 0.35x | Within |
| 2025-08-11 | After-Close | 18.27% | 3.08% | 0.17x | Within |
| 2025-11-10 | After-Close | 60.18% | 9.73% | 0.16x | Within |
| 2026-03-12 | After-Close | 11.79% | 8.13% | 0.69x | Within |
Options Activity
- IV Rank (30D)
- 20.23
- IV Rank (7D)
- 100
- Avg IV
- 115.2%
- Straddle (30D)
- $7.03
- Straddle (7D)
- $3.95
- P/C Volume
- 0.51
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 2.01
- Correlation (SPY)
- 6.4%
- R²
- 0.00
- Ann. Volatility
- 384.9%
- SPY Volatility
- 12.4%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 48,834,476 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
17 filers$120.28M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $31.97M | 26.58% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $17.15M | 14.26% | 2026-03-31 |
| 3 | GROUP ONE TRADING LLC Custodian | $12.25M | 10.19% | 2026-03-31 |
| 4 | Ikarian Capital, LLC | $10.64M | 8.85% | 2026-03-31 |
| 5 | DIADEMA PARTNERS LP | $10.01M | 8.32% | 2026-03-31 |
| 6 | D. E. Shaw & Co., Inc. Custodian | $9.58M | 7.96% | 2026-03-31 |
| 7 | JANE STREET GROUP, LLC Custodian | $9.39M | 7.80% | 2026-03-31 |
| 8 | Caption Management, LLC | $6.74M | 5.61% | 2026-03-31 |
| 9 | SIMPLEX TRADING, LLC Custodian | $3.31M | 2.75% | 2026-03-31 |
| 10 | BOOTHBAY FUND MANAGEMENT, LLC | $2.99M | 2.48% | 2026-03-31 |
| 11 | LMR Partners LLP | $2.65M | 2.20% | 2026-03-31 |
| 12 | Persistent Asset Partners Ltd | $998.96K | 0.83% | 2026-03-31 |
| 13 | CITIGROUP INC Custodian | $957.60K | 0.80% | 2026-03-31 |
| 14 | WOLVERINE TRADING, LLC Custodian | $655.78K | 0.55% | 2025-09-30 |
| 15 | J. Goldman & Co LP | $608.00K | 0.51% | 2026-03-31 |
| 16 | TUDOR INVESTMENT CORP ET AL | $218.88K | 0.18% | 2026-03-31 |
| 17 | HAP TRADING, LLC | $161.37K | 0.13% | 2025-09-30 |
9 filers$53.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | DIADEMA PARTNERS LP | $18.95M | 35.37% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $10.23M | 19.09% | 2026-03-31 |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $7.90M | 14.75% | 2026-03-31 |
| 4 | Caption Management, LLC | $4.46M | 8.33% | 2026-03-31 |
| 5 | JANE STREET GROUP, LLC Custodian | $4.15M | 7.74% | 2026-03-31 |
| 6 | GROUP ONE TRADING LLC Custodian | $3.89M | 7.26% | 2026-03-31 |
| 7 | SIMPLEX TRADING, LLC Custodian | $3.02M | 5.63% | 2026-03-31 |
| 8 | WOLVERINE TRADING, LLC Custodian | $786.94K | 1.47% | 2025-09-30 |
| 9 | Persistent Asset Partners Ltd | $188.40K | 0.35% | 2026-03-31 |
Insider Activity
Latest: 2026-05-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | Michael T Maurer | CHIEF COMMERCIAL OFFICER | Grant (A) | +80,000 opt | — | EDGAR | |
| 2026-05-19 | Anthony Bergmann | CHIEF FINANCIAL OFFICER | Exer (M) | +3,000 | $1.39 | $4.2K | EDGAR |
| 2026-05-14 | Frank Litvack | Director | Exer (M) | +3,937 | $1.39 | $5.5K | EDGAR |
| 2026-05-04 | Anthony Bergmann | CHIEF FINANCIAL OFFICER | Mixed | — | $17.44 | -$713.0K | EDGAR |
| 2026-05-04 | Karen Krasney | EVP, GENERAL COUNSEL | Mixed | — | $17.44 | -$713.0K | EDGAR |
| 2026-04-03 | Karimah Es Sabar | Director | Mixed | — | $17.59 | -$217.0K | EDGAR |
| 2026-04-01 | Karen Krasney | EVP, GENERAL COUNSEL | Mixed | — | $16.86 | -$662.6K | EDGAR |
| 2026-04-01 | Anthony Bergmann | CHIEF FINANCIAL OFFICER | Mixed | — | $16.65 | -$673.7K | EDGAR |
| 2026-04-01 | Karimah Es Sabar | Director | Mixed | — | $17.71 | -$2.96M | EDGAR |
| 2026-03-27 | Karen Krasney | EVP, GENERAL COUNSEL | Exer (M) | +2,500 | $1.39 | $3.5K | EDGAR |
| 2026-01-07 | Linda Marban | CHIEF EXECUTIVE OFFICER | Grant (A) | +157,500 opt | — | EDGAR | |
| 2026-01-07 | David B Musket | Director | Grant (A) | +15,500 opt | — | EDGAR | |
| 2026-01-07 | Philip J Gotwals | Director | Grant (A) | +15,500 opt | — | EDGAR | |
| 2026-01-07 | GEORGE W JR DUNBAR | Director | Grant (A) | +15,500 opt | — | EDGAR | |
| 2026-01-07 | Anthony Bergmann | CHIEF FINANCIAL OFFICER | Grant (A) | +52,500 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
16 insiders · @ $28.07
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Nippon Shinyaku Co Ltd | 10%+ Owner | 7,090,351 | $199.03M | $15.00M | 1 | 2024-09-24 |
| 2 | SINAI MEDICAL CENTER CEDARS | 10%+ Owner | 4,049,959 | $113.68M | $5.55M | 3 | 2017-05-11 |
| 3 | Eduardo Marban | 10%+ Owner | 3,433,511 | $96.38M | $80.2K | 1 | 2015-08-20 |
| 4 | Edward A. St. John | 10%+ Owner | 2,398,580 | $67.33M | $4.00M | 1 | 2016-03-18 |
| 5 | LOUIS J GRASMICK | Director | 1,136,755 | $31.91M | $268.2K | 2 | 2016-03-18 |
| 6 | Linda Marban | CHIEF EXECUTIVE OFFICER | 533,519 | $14.98M | $104.6K | 16 | 2026-01-07 |
| 7 | Frank Litvack | Director | 180,054 | $5.05M | $0 | 18 | 2026-05-14 |
| 8 | Louis Manzo | Director | 126,414 | $3.55M | $271.0K | 16 | 2023-02-23 |
| 9 | David B Musket | Director | 88,788 | $2.49M | -$85.1K | 22 | 2026-01-07 |
| 10 | EARL M JR COLLIER | Director | 57,606 | $1.62M | $28.3K | 16 | 2025-02-28 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 5.5 |
| EV/EBITDA | -12.2 |
| TTM Net Income | $-0.1B |
| TTM EPS | $-2.32 |
| ROE | -41.1% |